Metabolic adaptation of glucose-deprived macrophages involves partial gluconeogenesis
Macrophages are recruited to sites of infection contributing to the killing of bacteria, but also to malignant tumors, where they promote angiogenesis and suppress antitumor immune responses. The metabolic microenvironment in tumors is frequently depleted of important nutrients such as glucose. Here, we investigated metabolic adaptation strategies of macrophages to glucose deprivation using stable isotopic tracing. Lactate production was decreased, potentially indicating a reduction of glycolysis. In contrast, the contribution of glutamine to the tricarboxylic acid cycle via α-ketoglutarate and reductive carboxylation were increased. Moreover, gluconeogenesis, the reverse pathway of glycolysis, was activated in glucose-deprived macrophages, proceeding partially to the generation of glycolytic intermediates and glycerol-3-phosphate. The partial gluconeogenesis pathway was abrogated in human and murine macrophages lacking the initial gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK2, mitochondrial isoform). Partial gluconeogenesis was higher in anti-inflammatory, interleukin-4-stimulated compared to proinflammatory, interferon-γ/lipopolysaccharide-stimulated macrophages. Single-cell analysis and immunostaining revealed expression of PCK2 in macrophages from both lung cancer and normal lung. Low glucose conditions only partially modulated macrophage phenotypes, leading to reduced CD80 surface marker levels in proinflammatory, and enhanced vascular endothelial growth factor expression in anti-inflammatory macrophages. Our study reveals partial gluconeogenesis in glucose-deprived macrophages and shows that this versatile type of immune cells exhibits remarkable metabolic flexibility.
Authors
- Gabriele Bluemel
- Theresa Haitzmann
- Thomas O. Eichmann (ORCID: https://orcid.org/0000-0002-8521-2795)
- Leigh M. Marsh (ORCID: https://orcid.org/0000-0002-1754-9249)
- Katharina Schindlmaier (ORCID: https://orcid.org/0000-0002-6703-5123)
- Sonja Rittchen
- Vanessa Jäger (ORCID: https://orcid.org/0009-0003-7761-3606)
- Julia Kargl (ORCID: https://orcid.org/0000-0002-0870-0816)
- Cristina Muñoz‐Pinedo (ORCID: https://orcid.org/0000-0002-9120-664X)
- Katharina Leithner (ORCID: https://orcid.org/0000-0002-8252-9279)
- Barbara Konrad
- Luka Brčić (ORCID: https://orcid.org/0000-0002-9098-8416)
- Zlatko Trajanoski (ORCID: https://orcid.org/0000-0002-0636-7351)
- Michael A. Dengler (ORCID: https://orcid.org/0000-0002-1693-1761)
- Alexander Kirchmair (ORCID: https://orcid.org/0000-0003-2284-7424)
- Visnja Bubalo
- Jörg Lindenmann
- Joseph G Jelwan (ORCID: https://orcid.org/0009-0002-2533-4456)
Institutions
- Innsbruck Medical University (AT)
- University of Salzburg (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Ludwig Boltzmann Institute for Lung Vascular Research (AT)
- Bioanalytica (Switzerland) (CH)
- IONICS Mass Spectrometry (Canada) (CA)
- BioTechMed-Graz (AT)
- Institute for Biomedicine (IT)
- Institute of Bioinformatics (IN)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1073/pnas.2419568122
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Austrian Science Fund
- KU Leuven
- Vlaams Instituut voor Biotechnologie
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Bundesministerium für Bildung, Wissenschaft und Forschung
- HORIZON EUROPE European Innovation Council